Post-Conference Perspectives

MRD Assessment and Prognostic Factors for Myeloma
January 20, 2020 – 
Dr Chari reviews the MRD assessment and how he uses it in his practice.
Studies With a PI-Based Quadruplet Regimen and Sequencing
January 20, 2020 – 
The panelist describes the PI-based quadruplet regimen studies. He also discusses the practical sequencing of investigational treatment strategies with the current standard of care.
Treatment of Newly Diagnosed Symptomatic Myeloma and Dosing Regimens
January 17, 2020 – 
The expert reviews the standard for treatment of newly diagnosed symptomatic myeloma. He also reviews the different dosing regimens used.
Proteasome Inhibitor-Based Treatment Regimens
January 17, 2020 – 
Dr Chari discusses the use of proteasome inhibitors [PIs] in the treatment of multiple myeloma and the differences among the available agents.
Transplant Eligibility, NCCN Recommendations, and Sequencing
December 19, 2019 – 
Dr Ajai Chari defines when a patient is transplant eligible and what proportion of patients often are. He reviews the NCCN Guidelines and the standard sequencing of MM in transplant-eligible patients.
Reimbursement With Treatment for Multiple Myeloma
January 03, 2019 – 
Rafael Fonseca, MD, discusses the reimbursement status of the various treatment options for multiple myeloma.
Studies Presented at ASH 2018 and the Outlook for Myeloma
January 03, 2019 – 
Rafael Fonseca, MD, reviews the studies presented at ASH 2018—ARROW, OPTIMISMM, and ELOQUENT-3—and shares the outlook of therapy and unmet needs in myeloma.
MRD Testing and Relapsed/Refractory Multiple Myeloma Treatment Options
December 26, 2018 – 
Rafael Fonseca, MD, defines the clinical significance of minimal residual disease (MRD) testing and the approach to relapsed/refractory for myeloma.
Transplant Patients' Options, CoMMpass Study, and Doublet Versus Triplet Therapy
December 26, 2018 – 
Rafael Foseca, MD, reviews the NCCN guidelines for multiple myeloma and the transplant candidates VRD and KRD and discusses the CoMMpass trial.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.